Ceftriaxon hameln: Uses, Dosage & Side Effects

What Is Ceftriaxon hameln and What Is It Used For?

Ceftriaxone is a semi-synthetic, broad-spectrum, third-generation cephalosporin antibiotic that has been in clinical use since the early 1980s. It was originally developed by Hoffmann-La Roche and marketed under the brand name Rocephin. Ceftriaxon hameln is a generic formulation manufactured by hameln pharma, containing ceftriaxone as the disodium salt hemiheptahydrate in a powder form that is reconstituted with a suitable diluent before intravenous (IV) or intramuscular (IM) administration. The product is supplied as a 1 g vial of sterile powder.

Like all beta-lactam antibiotics, ceftriaxone works by interfering with bacterial cell wall synthesis. Specifically, it binds with high affinity to penicillin-binding proteins (PBPs), which are transpeptidase enzymes essential for the final cross-linking steps of peptidoglycan biosynthesis. When ceftriaxone inhibits these enzymes, the bacterial cell wall becomes structurally compromised, leading to osmotic instability, cell lysis, and bacterial death. Ceftriaxone is therefore classified as a bactericidal antibiotic. Importantly, ceftriaxone has high stability against hydrolysis by most clinically significant beta-lactamase enzymes (including TEM-1, TEM-2, and SHV-1), which gives it a significantly broader spectrum of activity compared to first- and second-generation cephalosporins.

A distinguishing pharmacokinetic feature of ceftriaxone is its unusually long elimination half-life. While most cephalosporins have half-lives of 1–2 hours, ceftriaxone has a half-life of approximately 5.8–8.7 hours in adults with normal renal function. This allows for once-daily dosing in most clinical scenarios, which is a significant advantage in terms of patient convenience, healthcare resource utilisation, and outpatient parenteral antibiotic therapy (OPAT) programmes. Ceftriaxone achieves high concentrations in most body tissues and fluids, including cerebrospinal fluid (CSF) when the meninges are inflamed, making it a first-line treatment for bacterial meningitis.

The long half-life of ceftriaxone is related to its high degree of protein binding (approximately 85–95% bound to plasma albumin). Elimination occurs through a dual pathway: approximately 33–67% of a dose is excreted unchanged in the urine by glomerular filtration, while the remainder is excreted via bile into the faeces. This dual elimination pathway means that mild to moderate impairment of either renal or hepatic function alone does not usually require dose adjustment, although patients with combined severe renal and hepatic impairment may need monitoring.

Ceftriaxone has a broad spectrum of antimicrobial activity. It is effective against many clinically important pathogens including:

• Gram-positive bacteria: Streptococcus pneumoniae (including penicillin-intermediate strains), Streptococcus pyogenes (Group A), Streptococcus agalactiae (Group B), and viridans group streptococci. Activity against Staphylococcus aureus is variable and limited to methicillin-susceptible strains (MSSA); ceftriaxone is not effective against methicillin-resistant S. aureus (MRSA).
• Gram-negative bacteria: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Haemophilus influenzae (including beta-lactamase producing strains), Neisseria meningitidis, Neisseria gonorrhoeae, Moraxella catarrhalis, Citrobacter species, and Enterobacter species (though inducible chromosomal AmpC beta-lactamases may cause resistance).
• Anaerobes: Some anaerobic bacteria are susceptible, but ceftriaxone has limited activity against Bacteroides fragilis and other important anaerobes.
• Spirochaetes: Borrelia burgdorferi (the causative agent of Lyme disease) and Treponema pallidum (the causative agent of syphilis, as an alternative therapy).

Ceftriaxone is indicated for the treatment of the following infections when caused by susceptible organisms:

• Bacterial meningitis: Ceftriaxone is a first-line empirical treatment for community-acquired bacterial meningitis in adults and children, providing excellent CSF penetration when the meninges are inflamed.
• Septicaemia (bloodstream infections): Empirical and directed treatment of sepsis and bacteraemia caused by susceptible organisms.
• Community-acquired pneumonia: Moderate to severe cases requiring hospitalisation, often as part of combination therapy with a macrolide antibiotic.
• Hospital-acquired pneumonia: Selected cases depending on local resistance patterns.
• Complicated urinary tract infections: Including acute pyelonephritis (kidney infection).
• Bone and joint infections: Including osteomyelitis and septic arthritis.
• Complicated intra-abdominal infections: Usually in combination with metronidazole for anaerobic coverage.
• Complicated skin and soft tissue infections: Severe cellulitis, wound infections, and infected burns.
• Acute otitis media: In children when oral therapy has failed or is not possible.
• Gonorrhoea: Ceftriaxone is now the recommended first-line treatment for uncomplicated gonococcal infections globally, including when resistance to other antibiotics is suspected.
• Lyme disease: Neuroborreliosis and disseminated Lyme disease.
• Syphilis: As an alternative treatment when penicillin is not suitable.
• Surgical prophylaxis: Prevention of post-operative infections, particularly in colorectal, gynaecological, and orthopaedic surgery.

Ceftriaxone is included on the WHO Model List of Essential Medicines, reflecting its critical importance in global healthcare. Under the WHO AWaRe classification system, ceftriaxone is classified as a Watch antibiotic, meaning it should be prioritised as a key target for stewardship programmes and monitoring because of its higher resistance potential compared to Access group antibiotics. This classification underscores the importance of using ceftriaxone judiciously and only when clinically indicated.

What Should You Know Before Receiving Ceftriaxon hameln?

Contraindications

There are specific situations in which Ceftriaxon hameln must not be used. Understanding these absolute contraindications is essential for safe treatment and preventing potentially life-threatening adverse events.

• Hypersensitivity to ceftriaxone or cephalosporins: Do not receive this medication if you have a known severe hypersensitivity (allergy) to ceftriaxone, to any other cephalosporin antibiotic, or to any of the excipients in the product. A history of anaphylaxis, angioedema, or severe skin reactions (such as Stevens-Johnson syndrome or toxic epidermal necrolysis) to any cephalosporin is an absolute contraindication.
• Severe hypersensitivity to other beta-lactams: Patients who have experienced a severe immediate hypersensitivity reaction (e.g., anaphylaxis) to any penicillin or other beta-lactam antibiotic should not receive ceftriaxone. The structural similarities between penicillins and cephalosporins mean cross-reactivity is possible, although the rate with third-generation cephalosporins is low (estimated at 1–2%).
• Neonates with hyperbilirubinaemia: Ceftriaxone is contraindicated in premature neonates up to a corrected gestational age of 41 weeks and in full-term neonates (up to 28 days of age) who have, or are expected to develop, hyperbilirubinaemia (jaundice). Ceftriaxone can displace bilirubin from albumin binding sites, potentially increasing free bilirubin levels and the risk of bilirubin encephalopathy (kernicterus).
• Neonates requiring calcium-containing IV solutions: Ceftriaxon hameln must not be administered to neonates (up to 28 days of age) if they require or are expected to require treatment with calcium-containing intravenous solutions, including continuous calcium-containing infusions such as parenteral nutrition. Fatal reactions due to ceftriaxone-calcium precipitates in the lungs and kidneys have been reported in neonates.

Warnings and Precautions

Before receiving Ceftriaxon hameln, inform your doctor or healthcare provider if any of the following conditions apply to you:

• History of any allergic reaction to antibiotics: Particularly penicillins or other beta-lactams. Even if your reaction was mild (e.g., a rash), it is important to inform your healthcare provider, as the risk of cross-reactivity exists. Patients with a general predisposition to allergic reactions (atopy, allergic rhinitis, asthma) may be at slightly increased risk.
• Kidney impairment: While mild to moderate renal impairment does not usually require dose adjustment (due to the dual elimination pathway), patients with severe renal impairment (creatinine clearance < 10 ml/min) should have their dose limited to a maximum of 2 g daily, and serum drug levels should be monitored if possible.
• Liver disease: Hepatic impairment alone does not usually require dose adjustment. However, in patients with concomitant severe renal and hepatic impairment, close monitoring of plasma ceftriaxone concentrations is recommended, as total clearance may be significantly reduced.
• Gallbladder disease: Ceftriaxone can form insoluble precipitates (calcium ceftriaxone) in the gallbladder, appearing as shadows on ultrasound imaging. This condition is known as biliary pseudolithiasis and is usually reversible upon discontinuation. It occurs more frequently at higher doses and with prolonged treatment. Patients with pre-existing gallbladder pathology or bile stasis may be at increased risk.
• Kidney stones: Ceftriaxone-calcium precipitates can also form in the kidneys (renal pseudolithiasis or nephrolithiasis). Risk factors include high doses, rapid IV injection, dehydration, and immobilisation. Adequate hydration should be maintained during treatment.
• Haemolytic anaemia: Immune-mediated haemolytic anaemia has been observed during treatment with cephalosporins including ceftriaxone. Severe cases of haemolytic anaemia, including fatalities, have been reported. If a patient develops anaemia during treatment, the diagnosis of cephalosporin-associated anaemia should be considered and ceftriaxone should be discontinued until the cause is established.
• Sodium content: Each gram of ceftriaxone contains approximately 3.6 mmol (83 mg) of sodium. This should be taken into account for patients on a controlled sodium diet.
• Antibiotic-associated diarrhoea: As with almost all antibiotics, Clostridioides difficile-associated diarrhoea (CDAD) has been reported with ceftriaxone. The severity can range from mild diarrhoea to fatal pseudomembranous colitis. If significant diarrhoea develops during or after treatment, contact your doctor immediately. Do not take anti-diarrhoeal medicines that stop bowel movements.
• Superinfection: Prolonged use may result in overgrowth of non-susceptible organisms, including fungi (e.g., Candida). If superinfection occurs, appropriate measures should be taken.

Pregnancy and Breastfeeding

Ceftriaxone crosses the placenta and reaches the fetal circulation. Animal reproductive studies have not demonstrated direct harmful effects on fertility, embryonic or fetal development, or postnatal development. However, as with all medications during pregnancy, ceftriaxone should only be used when the expected benefit to the mother outweighs the potential risk to the fetus. There are no adequate and well-controlled studies in pregnant women from randomised controlled trials, but extensive clinical experience over several decades supports its relative safety when clinically indicated.

Ceftriaxone is excreted in human breast milk at low concentrations (approximately 3–4% of maternal plasma concentrations). At therapeutic doses, minimal effects on the breastfed infant are expected. However, the possibility of sensitisation (development of allergy), diarrhoea, or disruption of the infant’s bowel flora (including candidiasis) should be considered. A decision should be made whether to discontinue breastfeeding or to discontinue ceftriaxone therapy, taking into account the benefit of breastfeeding for the infant and the benefit of therapy for the mother. If your breastfed infant develops diarrhoea, skin rash, or oral thrush while you are receiving ceftriaxone, inform your doctor.

Ceftriaxone has not been shown to impair fertility in animal studies at doses relevant to human therapeutic use. No human fertility data from controlled studies are available.

How Does Ceftriaxon hameln Interact with Other Drugs?

Drug interactions with ceftriaxone are relatively limited compared to many other antibiotics, but some are clinically significant and potentially dangerous. Understanding these interactions is essential for safe prescribing and administration.

Major Interactions

Minor Interactions

It is important to note that ceftriaxone must not be reconstituted or mixed with solutions containing calcium, including Ringer’s lactate solution and Hartmann’s solution. Ceftriaxone should not be mixed with other antibiotics in the same syringe or infusion bag. In the context of aminoglycoside combination therapy, the two drugs should be administered at separate sites or sequentially with adequate flushing of the line between administrations.

Always inform your healthcare team about all medications you are currently receiving, including prescription drugs, over-the-counter medicines, herbal remedies, and supplements. This is particularly important for anticoagulant therapy, where close monitoring of coagulation parameters is essential during concurrent ceftriaxone treatment.

What Is the Correct Dosage of Ceftriaxon hameln?

Ceftriaxon hameln is supplied as a powder for reconstitution. The dose, route of administration, and duration of treatment are determined by the prescribing physician based on the type and severity of infection, the patient’s age and weight, renal and hepatic function, and local antimicrobial susceptibility patterns. The following are general guidelines based on international recommendations (EMA SmPC, BNF, WHO guidelines).

Adults and Adolescents (≥12 years, ≥50 kg)

Children and Infants (15 days to 12 years, <50 kg)

Neonates (0–14 days)

Elderly Patients

In elderly patients with normal renal and hepatic function, no dose adjustment is required. However, elderly patients are more likely to have reduced renal function and may be more susceptible to adverse effects. Renal function should be assessed before and during treatment, and doses should be adjusted if creatinine clearance falls below 10 ml/min. Elderly patients may also be at increased risk for biliary complications (pseudolithiasis) and Clostridioides difficile-associated diarrhoea.

Missed Dose

Because Ceftriaxon hameln is typically administered by healthcare professionals in a clinical setting, missed doses are uncommon. However, if a dose is missed, it should be given as soon as practicable, and the regular dosing schedule should then be resumed. Do not give a double dose to compensate for a missed dose. In outpatient parenteral antibiotic therapy (OPAT) programmes where patients receive ceftriaxone at home via a visiting nurse, it is important to adhere to the prescribed schedule as closely as possible to maintain adequate blood levels.

Overdose

In the event of overdose, drug concentration cannot be reduced by haemodialysis or peritoneal dialysis, as ceftriaxone is highly protein-bound. There is no specific antidote. Treatment of overdose should be supportive and symptomatic. Symptoms of overdose may include nausea, vomiting, and diarrhoea. Very high CSF concentrations of ceftriaxone may provoke neurological symptoms including convulsions. In cases of severe renal impairment combined with hepatic impairment, the risk of accumulation and toxicity is increased.

What Are the Side Effects of Ceftriaxon hameln?

Like all medicines, Ceftriaxon hameln can cause side effects, although not everybody gets them. The following frequency classification is used: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), and not known (cannot be estimated from available data).

The most clinically significant adverse effect of ceftriaxone is immune-mediated haemolytic anaemia, which, although rare, can be life-threatening and has resulted in fatal outcomes. It typically occurs after several days of treatment and is characterised by a sudden drop in haemoglobin, positive direct Coombs test, and evidence of red blood cell destruction. If haemolytic anaemia is suspected, ceftriaxone must be discontinued immediately.

Biliary pseudolithiasis is a relatively unique side effect of ceftriaxone related to its biliary excretion. Calcium-ceftriaxone precipitates can form in the gallbladder, particularly at higher doses, with prolonged therapy, and in patients with risk factors such as dehydration, fasting, or total parenteral nutrition. It is usually asymptomatic and detected incidentally on ultrasound, but can sometimes cause symptoms mimicking gallstones (biliary colic, cholecystitis). The condition is reversible upon discontinuation of ceftriaxone and does not require surgery.

If you experience any side effects, including those not listed above, inform your healthcare provider. You can also report side effects directly through your national pharmacovigilance reporting system.

How Should You Store Ceftriaxon hameln?

Correct storage of Ceftriaxon hameln is essential to ensure the medicine remains effective and safe. The storage requirements differ for the unopened powder and the reconstituted solution.

Unopened powder: Store the sealed vials at temperatures not exceeding 25°C. Keep the vials in the outer carton to protect from light. Do not freeze. The shelf life of the unopened product is stated on the packaging (typically 3 years from manufacture). Do not use after the expiry date printed on the label and carton.

Reconstituted solution: Chemical and physical in-use stability has been demonstrated for up to 6 hours at 25°C (or up to 24 hours at 2–8°C) when reconstituted with the recommended diluents. However, from a microbiological point of view, the product should be used immediately after reconstitution. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should not normally be longer than the stated times unless reconstitution has taken place in controlled and validated aseptic conditions.

Visual inspection: The reconstituted solution should be a clear to slightly opalescent yellow to amber solution. Do not use the solution if it appears cloudy, contains visible particles, or has changed colour beyond the expected range. Any unused solution should be discarded.

Keep all medicines out of the sight and reach of children. Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use or that have expired. These measures help protect the environment.

What Does Ceftriaxon hameln Contain?

Ceftriaxon hameln has a simple formulation consisting of the active ingredient without additional excipients:

• Active substance: Ceftriaxone 1 g per vial, present as ceftriaxone disodium salt hemiheptahydrate (equivalent to approximately 1.193 g of the salt form per vial). Ceftriaxone disodium is a white to yellowish-orange crystalline powder that is freely soluble in water.
• Excipients: None. The powder contains no additional inactive ingredients, preservatives, or diluents.
• Sodium content: Each gram of ceftriaxone contains approximately 3.6 mmol (83 mg) of sodium. This is relevant for patients on a sodium-restricted diet and should be factored into total daily sodium intake calculations, especially at higher doses.

Reconstitution diluents (not included in the vial): Ceftriaxon hameln powder must be reconstituted before use with an appropriate diluent. For intravenous injection, the recommended diluent is Water for Injections. For intravenous infusion, suitable diluents include 0.9% sodium chloride solution, 5% glucose solution, or 10% glucose solution. For intramuscular injection, the powder is typically dissolved in 1% lidocaine hydrochloride solution to reduce injection pain (not for IV use). Do not reconstitute with calcium-containing solutions (Ringer’s lactate, Hartmann’s solution, or any solution containing calcium).

Appearance: The powder is white to yellowish in colour. When reconstituted, the solution ranges from pale yellow to amber depending on concentration and diluent used. This colouration does not indicate loss of potency and is a normal characteristic of ceftriaxone solutions.

Packaging: Ceftriaxon hameln is available as clear glass vials containing ceftriaxone 1 g powder, sealed with a rubber stopper and aluminium cap. Pack sizes vary by market.